about
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic CancerDesigns for phase I trials in ordered groups.Performance of toxicity probability interval based designs in contrast to the continual reassessment method.Dimension of model parameter space and operating characteristics in adaptive dose-finding studies.Implementation of adaptive methods in early-phase clinical trials.Ethical considerations concerning treatment allocation in drug development trials.Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.Performance of two-stage continual reassessment method relative to an optimal benchmarkPhase I/II adaptive design for drug combination oncology trialspocrm: an R-package for phase I trials of combinations of agents.Using the time-to-event continual reassessment method in the presence of partial ordersContinual reassessment method for partial ordering.Obtaining the optimal dose in alcohol dependence studies.Dose-finding design for multi-drug combinations.Extended model-based designs for more complex dose-finding studies.Continual Reassessment and Related Dose-Finding DesignsDesigns for single- or multiple-agent phase I trials.Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.Dose finding with longitudinal data: simpler models, richer outcomes.Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.Bridging Solutions in Dose Finding Problems.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.Adaptive design clinical trials: Methodology, challenges and prospectContinual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor ConsortiumLearning from previous responses in phase I dose-escalation studiesWhat does a modified-Fibonacci dose-escalation actually correspond to?Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsCompeting designs for phase I clinical trials: a review.Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.Incorporating lower grade toxicity information into dose finding designs.Stochastic approximation with virtual observations for dose-finding on discrete levels.The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.Experimental designs for phase I and phase I/II dose-finding studies.Effective dose of nefopam in 80% of patients (ED80): a study using the continual reassessment methodInterplay of priors and skeletons in two-stage continual reassessment method.Adaptive prior variance calibration in the Bayesian continual reassessment method.
P2860
Q26823418-EAD775BE-3E69-4703-BD27-7C28E5E0C529Q28552089-226AB609-062C-4093-A323-B0779AB38321Q30275947-FC947F98-2B8D-4CB8-9716-5AF21A50AEFDQ30276332-B2C8A94D-16E8-4DA3-9278-78A986D8E832Q30276967-B34106EA-2AF4-472E-AA98-FECD89F98908Q30277243-E838DAE7-A7CD-4DE4-A644-90226C1E2B76Q30332007-8A8E99A3-FB4B-4EB9-B650-BCBEFABADD26Q30371414-449F354C-930C-46B7-A3F8-2BEB64A6CA45Q30407451-DB40113C-8064-4A21-A3CA-1B0671D6995FQ30409168-5EF13859-0E47-4FD9-9AA3-FCB2058D2889Q30410385-3C84DACB-D0EA-4B56-81F0-6811829EFEDFQ30422422-1A3DD60D-1F47-4840-B7E0-176BAFF9A9C2Q30423577-1978F369-C91E-4C1F-9E71-0E793810932FQ30423823-7A146327-704B-46C4-9D7C-8048F39E3829Q30424392-9CA2A622-39D9-4C08-A420-5189AB33A780Q30424442-6E8CA818-79AB-48D5-91A9-4195A8A24ABDQ30431500-8AC4753F-98CF-4EF0-8714-27D44C188452Q30434355-F909FACC-6BA6-419C-AD43-CDAEE1CC412DQ30665810-D1667BF0-427F-47A9-8145-92A7043BCD4FQ30976631-E509D719-E8FC-4DA3-916B-7014DF62C7A5Q33393931-7280D6EE-64D8-469D-B6BA-A85D52EB90C1Q33414645-572E5894-CB06-4371-BF4C-C418FEB5B0F2Q33772533-E10CE805-58BE-4C6D-8E1F-8E8D4253716CQ33951160-7FD241B6-F71E-4BED-816D-61CBA4F9AFECQ34001009-4DF7598A-41F5-4312-9536-34F362DD9C93Q34138180-5F697C34-8B35-4592-9696-1D44BEDD65D8Q34292228-0475DF25-E9F7-4FAD-9565-B984930879B4Q34308804-59A632EF-9538-4165-A584-21A48225E919Q34348422-6FDCC933-CDC9-4C10-8AA5-52AB0B87C76EQ34480582-17E2FC35-FFB5-47F2-B1D2-CAAEB314F945Q34849945-E453A9C0-12C3-425D-8857-CB46C5BDF579Q35113331-279D2077-014D-4D1F-83D5-6FC2CCCF2EF5Q35161796-DEC2AAD3-B166-474E-8168-39973EF8267AQ35800784-CE7C5A7D-2301-4A36-91D2-D65526C1D3ADQ36142945-B8494D51-6338-49AE-80F1-B30393F3CF81Q36295897-05F01548-22B2-450D-8F90-BFF87F0A39D1Q36376785-A95CB980-E347-48A6-AB80-39E116D29CA2Q36388111-00E36A10-50DA-4E4D-9DFD-5E9E809ADA94Q36513919-FCB33ED5-32C8-4826-A982-5EA46E2A682EQ36579392-D7F4FE31-9587-49EB-A204-47154A1066E1
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Continual reassessment method: a likelihood approach.
@en
Continual reassessment method: a likelihood approach.
@nl
type
label
Continual reassessment method: a likelihood approach.
@en
Continual reassessment method: a likelihood approach.
@nl
prefLabel
Continual reassessment method: a likelihood approach.
@en
Continual reassessment method: a likelihood approach.
@nl
P356
P1433
P1476
Continual reassessment method: a likelihood approach.
@en
P2093
P304
P356
10.2307/2532905
P407
P577
1996-06-01T00:00:00Z